About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Contact Us
R&D and science
R&D Platform
Pipelines
Products Center
Manufacturing
Subject Recruitment
Expanded Access Policy
Collaborations
Investor Relations
Listing Documents
Financial Reports
Presentations
Investor Relations Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Career
Meet Our People
Now Hiring
简
|
EN
|
Akeso News
Monthly News
2021-01-15
For Treatment of COVID-19 Akesobio Doses First Healthy Subject with CD73 Monoclonal Antibody (AK119)
2020-07-30
Akeso, Inc. Promotes the Deployment of Innovative Pipeline Global Cooperation Appoints Dr. Michael (Chen) Chen as Business Development Vice President
2020-07-03
康方生物董事长兼首席执行官夏瑜女士入选2020福布斯“中国科技女性榜”
2020-05-25
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
2020-05-11
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
2020-04-02
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer